Protocol Ledger

NCT03403751 · Phase III · TERMINATED

Phase 3 Study of Reltecimod vs Placebo in Patients With Sepsis-associated Acute Kidney Injury

Interventional Phase III clinical trial protocol NCT03403751 sponsored by Atox Bio in Infectious Disease and Vaccines, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2018-05-24 Enrollment: 58 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT03403751
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)58 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT03403751
Protocol FieldVerified Registry Value
NCT IdentifierNCT03403751
Consolidated Lead SponsorAtox Bio
Therapeutic Condition CohortInfectious Disease and Vaccines
Clinical Trial PhasePhase III
Overall Recruitment StatusTERMINATED
Registered Enrollment58 participants (ACTUAL)
Registered Start Date2018-05-24
WhyStopped ClassificationInsufficient / Slow Accrual

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Infectious Disease and Vaccines Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI